OSE Immunotherapeutics SA (OSE.PA)
EUR 7.17
(-1.38%)
EUR 7.17
(-1.38%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.22 Million EUR | -87.83% |
| 2022 | 18.3 Million EUR | -30.43% |
| 2021 | 26.3 Million EUR | 152.48% |
| 2020 | 10.41 Million EUR | -59.84% |
| 2019 | 25.94 Million EUR | 6.1% |
| 2018 | 24.45 Million EUR | 265.94% |
| 2017 | 6.68 Million EUR | 1720.71% |
| 2016 | 367 Thousand EUR | 4177.78% |
| 2015 | -9000.00 EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 69.04 Million EUR | 0.0% |
| 2023 Q2 | 1.35 Million EUR | 0.0% |
| 2023 Q4 | 869 Thousand EUR | 0.0% |
| 2023 FY | 2.22 Million EUR | -87.83% |
| 2022 Q2 | 16.04 Million EUR | 0.0% |
| 2022 Q4 | 2.25 Million EUR | 0.0% |
| 2022 FY | 18.3 Million EUR | -30.43% |
| 2021 FY | 26.3 Million EUR | 152.48% |
| 2021 Q4 | 17.33 Million EUR | 0.0% |
| 2021 Q2 | 8.97 Million EUR | 0.0% |
| 2020 Q4 | 4.57 Million EUR | 0.0% |
| 2020 FY | 10.41 Million EUR | -59.84% |
| 2020 Q2 | 5.84 Million EUR | 0.0% |
| 2019 Q4 | 9.97 Million EUR | 0.0% |
| 2019 Q2 | 15.97 Million EUR | 0.0% |
| 2019 FY | 25.94 Million EUR | 6.1% |
| 2018 FY | 24.45 Million EUR | 265.94% |
| 2018 Q2 | 20.6 Million EUR | 0.0% |
| 2018 Q4 | 3.84 Million EUR | 0.0% |
| 2017 FY | 6.68 Million EUR | 1720.71% |
| 2017 Q4 | 3.83 Million EUR | 0.0% |
| 2017 Q2 | 2.84 Million EUR | 0.0% |
| 2016 FY | 367 Thousand EUR | 4177.78% |
| 2016 Q4 | 344 Thousand EUR | 0.0% |
| 2016 Q2 | 39 Thousand EUR | 0.0% |
| 2015 FY | -9000.00 EUR | 0.0% |
| 2015 Q4 | 3000.00 EUR | 0.0% |
| 2015 Q2 | 1000.00 EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -260.356% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 43.102% |
| Adocia SA | 1.38 Million EUR | -60.794% |
| Aelis Farma SA | 12.35 Million EUR | 81.979% |
| Biophytis S.A. | -803 Thousand EUR | 377.335% |
| Advicenne S.A. | 1.42 Million EUR | -56.171% |
| genOway Société anonyme | 20.1 Million EUR | 88.921% |
| IntegraGen SA | 5.01 Million EUR | 55.622% |
| Medesis Pharma S.A. | -2.66 Million EUR | 183.572% |
| Neovacs S.A. | 29.31 Thousand EUR | -7497.053% |
| NFL Biosciences SA | -56.06 Thousand EUR | 4072.246% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -3.441% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 256.91% |
| Sensorion SA | 3.78 Million EUR | 41.207% |
| Theranexus Société Anonyme | -4.63 Million EUR | 148.009% |
| TME Pharma N.V. | -127 Thousand EUR | 1853.543% |
| Valbiotis SA | 2.66 Million EUR | 16.529% |
| TheraVet SA | -530.79 Thousand EUR | 519.559% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -75.77% |
| argenx SE | 925.49 Million EUR | 99.759% |
| BioSenic S.A. | 543 Thousand EUR | -310.129% |
| Celyad Oncology SA | 33 Thousand EUR | -6648.485% |
| DBV Technologies S.A. | 4.15 Million EUR | 46.461% |
| Galapagos NV | 203.73 Million EUR | 98.907% |
| Genfit S.A. | 28.22 Million EUR | 92.11% |
| GeNeuro SA | -293.8 Thousand EUR | 857.999% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | -11.685% |
| Innate Pharma S.A. | -4.12 Million EUR | 154.04% |
| Inventiva S.A. | 17.5 Million EUR | 87.274% |
| MaaT Pharma SA | 1.65 Million EUR | -34.562% |
| MedinCell S.A. | 9.28 Million EUR | 76.023% |
| Nanobiotix S.A. | 36.2 Million EUR | 93.849% |
| Onward Medical N.V. | -14.81 Million EUR | 115.029% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 84.033% |
| Oxurion NV | 104 Thousand EUR | -2041.346% |
| Pharming Group N.V. | 220.1 Million EUR | 98.988% |
| Poxel S.A. | 1000.00 EUR | -222600.0% |
| GenSight Biologics S.A. | 3 Million EUR | 25.767% |
| Transgene SA | -28.4 Million EUR | 107.84% |
| Financière de Tubize SA | -2.02 Million EUR | 209.727% |
| UCB SA | 3.34 Billion EUR | 99.933% |
| Valneva SE | 52.83 Million EUR | 95.785% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 171.955% |